U.S. Code · Título 21
Risk communication
21 U.S.C. § 360bbb–6
Office of the Law Revision Counsel · release 119-142
Se muestra el texto operativo de la sección. Las notas estatutarias y el historial de enmiendas están en la fuente oficial.
Advisory Committee on Risk Communication
In general
The Secretary shall establish an advisory committee to be known as the “Advisory Committee on Risk Communication” (referred to in this section as the “Committee”).
Duties of Committee
The Committee shall advise the Commissioner on methods to effectively communicate risks associated with the products regulated by the Food and Drug Administration.
Members
The Secretary shall ensure that the Committee is composed of experts on risk communication, experts on the risks described in subsection (b), and representatives of patient, consumer, and health professional organizations.
Permanence of Committee
Section 1013 of title 5 shall not apply to the Committee established under this subsection.
Partnerships for risk communication
In general
The Secretary shall partner with professional medical societies, medical schools, academic medical centers, and other stakeholders to develop robust and multi-faceted systems for communication to health care providers about emerging postmarket drug risks.
Partnerships
The systems developed under paragraph (1) shall—
(June 25, 1938, ch. 675, § 567, as added Pub. L. 110–85, title IX, § 917, Sept. 27, 2007, 121 Stat. 960; amended Pub. L. 117–286, § 4(a)(157), Dec. 27, 2022, 136 Stat. 4323.)